Skip to main content
Article thumbnail
Location of Repository

The Analysis of Novel Gene Targets in Breast Cancer in Women ≤35 years.

By Sinéad Marie Lambe


Breast cancer presenting in women aged ≤ 35 years has a more aggressive behaviour, and\ud thus poorer prognosis, which is thought to be due to differences in the tumour biology of these tumours compared to those from older women.\ud The aim of this study was to examine the expression of 9 novel gene targets (A-kinase anchor protein-1 (AKAP1), Acidic protein rich in leucines (APRIL), CCAAT enhancer binding protein alpha (C/EBPα), Damage-specific DNA binding protein 2 (DDB2), Granulin, Nuclear Receptor Coactivator 3 (NCOA3), Retinoic acid receptor Responder 3 (RARRES3), Retinoblastoma binding protein 4 (RBBP4), and Transforming Growth Factor beta Induced (TGFβI) identified previously by a cDNA microarray in breast cancers and female controls by RT-qPCR, western blotting, and immunohistochemistry.\ud Six breast cell lines, 9 samples of organoids from reduction mammoplasty tissues, and 35 tumour tissues (20 cases >35 years, 15 cases ≤35 years in age) were analysed for the expression of the nine target genes using real time quantitative RT-PCR. Of the nine target genes investigated, five showed differences between normal and cancers ≤35, or between breast cancers ≤35 and those >35 years. NCOA3 and RARRES3 showed elevated levels of mRNA in breast cancers ≤35 years compared to those >35 years (p= 0.001 and p=0.002 respectively). Compared to the normal breast, TGFβI showed a reduced level of mRNA expression in both younger and older cases (p= 0.026 and p=0.001 respectively), while DDB2 and C-EBPα showed a reduced level of mRNA expression in younger group only (p=0.002 and p=0.001 respectively).\ud NCOA3 protein expression examination using western blotting found high levels in the\ud ER+ve cell lines MCF-7, ZR-75-1 and T47-D with a weak expression in ER−ve cell lines\ud HBL-100 and MDA-MB-468. RARRES3 protein expression was found in 4 breast cell lines\ud (HBL-100, MDA-MB-468, MCF-7, and ZR-75-1). IHC found expression of NCOA3 in\ud younger and older tumours including ER+ve and ER−ve cases.\ud This study identifies NCAO3 and RARRES3 as potential markers for breast cancers in\ud younger women, but the data need confirmation in a larger series of cases

Publisher: University of Leicester
Year: 2008
OAI identifier:

Suggested articles


  1. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
  2. (1993). A 127 kDa component of a UV-damaged DNA-binding complex, which is defective in some xeroderma pigmentosum group E patients, is homologous to a slime mold protein.
  3. (1982). A cell line (HBL-100) established from human breast milk.
  4. (1996). A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.
  5. (2003). A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.
  6. (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
  7. (2002). A gene-expression signature as a predictor of survival in breast cancer.
  8. (2003). A model of FAS1 domain 4 of the corneal protein beta(ig)-h3 gives a clearer view on corneal dystrophies.
  9. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
  10. (2001). A new mathematical model for relative quantification in real-time RTPCR.
  11. (1999). A newly identified patient with clinical xeroderma pigmentosum phenotype has a non-sense mutation in the DDB2 gene and incomplete repair in (6-4) photoproducts.
  12. (1992). A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells.
  13. (2003). A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase.
  14. (2003). A real-time polymerase chain reaction-based evaluation of cDNA synthesis priming methods.
  15. (1993). A retinoblastoma-binding protein related to a negative regulator of Ras in yeast.
  16. (1998). A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity.
  17. (2004). A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.
  18. (2000). ABC of breast diseases. Breast cancerepidemiology, risk factors, and genetics.
  19. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
  20. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
  21. (2004). ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.
  22. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
  23. (1999). Adolescence and breast carcinoma risk.
  24. (1995). Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features.
  25. (2001). AIB1 enhances estrogen-dependent induction of cyclin D1 expression.
  26. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.
  27. (2003). AKAP149 is a novel PP1 specifier required to maintain nuclear envelope integrity in G1 phase.
  28. (1998). Alcohol and breast cancer in women: a pooled analysis of cohort studies.
  29. (1999). Alcohol dehydrogenase 3 genotype modification of the association of alcohol consumption with breast cancer risk.
  30. (2004). aldolase b are up or down-regulated in human primary hepatocellular carcinoma.
  31. (2000). Altered expression of estrogen receptor coregulators during human breast tumorigenesis.
  32. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
  33. amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
  34. (2007). Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
  35. (1999). Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples.
  36. (2002). Analysis of gene expression in ductal carcinoma in situ of the breast.
  37. (2003). and susceptibility to breast cancer.
  38. (2000). Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer.
  39. (2004). Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin.
  40. (1995). Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro.
  41. (1994). beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice.
  42. (1998). Biological role of the CCAAT/enhancerbinding protein family of transcription factors.
  43. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
  44. (2007). BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
  45. (2003). BRCA1: a scaffold for p53 response?
  46. (1996). BRCA2 mutations in primary breast and ovarian cancers.
  47. (1987). Breast and other cancers in families with ataxia-telangiectasia.
  48. (2003). Breast and ovarian cancer.
  49. (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
  50. (2003). Breast cancer in young women (< or = 35 years): Genomic aberrations detected by comparative genomic hybridization.
  51. (1999). Breast cancer in young women: clinicopathologic correlation.
  52. (1994). Breast cancer outcome and predictors of outcome: are there age differentials?
  53. (2001). Breast cancer: hormones and other risk factors.
  54. (2003). Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
  55. (2006). Breast carcinoma in women 35 years and younger: a pathological study.
  56. (1998). Breast carcinoma tumor characteristics in black and white women.
  57. (1996). Breast carcinomas occurring in young women (< 35 years) are different.
  58. (2003). Breast cell invasive potential relates to the myoepithelial phenotype.
  59. (1998). C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation.
  60. (2000). C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.
  61. (2000). c-Myc in breast cancer.
  62. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism.
  63. (2005). c-Mycregulated microRNAs modulate E2F1 expression.
  64. (2001). C/EBPalpha arrests cell proliferation through direct inhibition of
  65. (2000). C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription.
  66. (1998). C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland.
  67. (1992). Cancer Incidence in Five Continents. Comparability and quality of data.
  68. (2007). Cancer Statistics registrations: Registrations of cancer diagnosed
  69. (2005). Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue.
  70. (1996). CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein.
  71. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.
  72. (1994). Changing trends. An overview of breast cancer incidence and mortality.
  73. (2002). Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.
  74. (2005). Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation.
  75. (2004). Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.
  76. (1995). Chromosomal localization and cDNA cloning of the genes (DDB1 and DDB2) for the p127 and p48 subunits of a human damage-specific DNA binding protein.
  77. (1996). Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
  78. (2001). Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients.
  79. (2003). Clinical significance of AIB1 expression in human breast cancer.
  80. (2004). Coactivator AIB1 links estrogen receptor transcriptional activity and stability.
  81. (2002). Combinatorial control of gene expression by nuclear receptors and coregulators.
  82. (2006). Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.
  83. (1997). Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma.
  84. (1998). Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.
  85. (1999). Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer.
  86. (2000). Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines.
  87. (1992). Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant.
  88. (2005). Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma.
  89. (1995). Cured of breast cancer?
  90. (2003). Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis.
  91. (1995). Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
  92. (1996). Cyclin D1 and prognosis in human breast cancer.
  93. (1994). Cyclin E, a potential prognostic marker for breast cancer.
  94. (1990). Cytochrome P450dbl phenotypes in malignant and benign breast disease.
  95. (2007). Ddb2 is a haploinsufficient tumor suppressor and controls spontaneous germ cell apoptosis.
  96. (2005). Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma.
  97. (2007). Defective Cell Cycle Checkpoint Functions in Melanoma Are Associated with Altered Patterns of Gene Expression.
  98. (2005). Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction.
  99. (2003). Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
  100. (1999). Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes.
  101. (2006). Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a casecontrol study.
  102. (2001). Differential gene expression profiling in human brain tumors.
  103. (2003). Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis.
  104. (2006). Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity.
  105. (2002). Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays.
  106. (1999). Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.
  107. (2006). DNA damage binding protein component DDB1 participates in nucleotide excision repair through DDB2 DNA-binding and cullin 4A ubiquitin ligase activity.
  108. (1991). DNA/RNA content and proliferative fractions of colorectal carcinomas: a five-year prospective study relating flow cytometry to survival.
  109. (2001). Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
  110. (2005). Downregulation and growth inhibitory role of C/EBPalpha in breast cancer.
  111. (1997). Dual effects of weight and weight gain on breast cancer risk.
  112. (2005). E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast.
  113. (2002). E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?
  114. (2001). E-cadherin as a prognostic indicator in primary breast cancer.
  115. (1996). E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma.
  116. (1997). Early-onset breast cancer--histopathological and prognostic considerations.
  117. (2000). Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR.
  118. (2005). Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer.
  119. (2001). Effects of mammographic density and benign breast disease on breast cancer risk (United States).
  120. (2006). Effects of young age at presentation on survival in breast cancer.
  121. (2000). Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells.
  122. (2005). Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation.
  123. (2007). Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat.
  124. (1979). Establishment and characterization of a cell line of human breast carcinoma origin.
  125. (1978). Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.
  126. (1978). Estrogen receptor assay in primary breast cancer and early recurrence of the disease.
  127. (2002). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.
  128. (1991). Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
  129. (1973). Estrogen receptor in a human cell line (MCF-7) from breast carcinoma.
  130. (2007). Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
  131. (2003). Ethnicity-related variation in breast cancer risk factors.
  132. (2005). Evaluation of housekeeping genes in placental comparative expression studies.
  133. Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines.
  134. (1993). Expression and amplification of cyclin genes in human breast cancer.
  135. (2005). Expression and regulation of retinoid-inducible gene 1 (RIG1) in breast cancer.
  136. (2000). Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer.
  137. (1998). Expression of CCAAT/enhancer binding proteins (C/EBP) is associated with squamous differentiation in epidermis and isolated primary keratinocytes and is altered in skin neoplasms.
  138. (1993). Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis.
  139. (2004). Expression of estrogen receptor coregulators in normal and malignant human endometrium.
  140. (2007). Expression of MMP-10 in lung cancer.
  141. (2003). Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium.
  142. (2001). Expression of progranulin and the epithelin/granulin precursor acrogranin correlates with neoplastic state in renal epithelium.
  143. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
  144. (2003). Expression of TGF-beta-induced matrix protein betaig-h3 is up-regulated in the diabetic rat kidney and human proximal tubular epithelial cells treated with high glucose.
  145. (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair.
  146. (2006). Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters.
  147. (2001). Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics.
  148. (2006). Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation.
  149. (2003). Further observations on LKB1/STK11 status and cancer risk in PeutzJeghers syndrome.
  150. (2005). GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues.
  151. (2006). Gene expression analysis by cDNA microarray in oral squamous cell carcinoma.
  152. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
  153. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
  154. (2004). Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors.
  155. (2003). Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
  156. (2000). Gene expression profiling of primary breast carcinomas using arrays of candidate genes.
  157. (2002). Gene expression profiling predicts clinical outcome of breast cancer.
  158. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
  159. (2006). Genes associated with breast cancer metastatic to bone.
  160. (2000). Genetic changes in breast cancer detected by comparative genomic hybridisation.
  161. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
  162. (1996). Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.
  163. (2003). Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis.
  164. (2006). GEP associates with wild-type p53 in hepatocellular carcinoma.
  165. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.
  166. (1994). Germline p53 mutations and heritable cancer.
  167. (2001). Global cancer statistics in the year
  168. (1999). Global cancer statistics.
  169. (2004). Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
  170. (2004). Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma.
  171. (2001). GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene.
  172. (2005). HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
  173. (2001). High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood.
  174. (1997). Histone deacetylase activity is required for full transcriptional repression by mSin3A.
  175. (1997). Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex.
  176. (2004). Housekeeping genes as internal standards in cancer research.
  177. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
  178. (2000). Human damage-specific DNA-binding protein p48. Characterization of XPE mutations and regulation following UV irradiation.
  179. (1998). Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.
  180. (2005). Identification and characterization of the retinoic acid response elements in the human RIG1 gene promoter.
  181. (2002). Identification of high risk breast-cancer patients by gene expression profiling.
  182. Identification of metastasis-associated genes by transcriptional profiling of a pair of metastatic versus non-metastatic human mammary carcinoma cell lines.
  183. (2002). Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin.
  184. (2005). Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator.
  185. (2007). Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity.
  186. (2005). Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
  187. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?
  188. (2005). Immunohistochemical evaluation of cyclin D1 in breast cancer.
  189. (2003). Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53.
  190. (1998). In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity.
  191. (1987). Incidence of female breast cancer among atomic bomb survivors,
  192. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families.
  193. (1996). Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha.
  194. (2002). Induction and expression of betaig-h3 in pancreatic cancer cells.
  195. (2006). Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a populationbased cohort study.
  196. (2000). Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468.
  197. (2005). Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes.
  198. (2004). International Human Genome Sequencing Consortium :Finishing the euchromatic sequence of the human genome.
  199. (1997). Kerato-epithelin mutations in four 5q31-linked corneal dystrophies.
  200. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21.
  201. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
  202. (1978). Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
  203. (1998). Long-term outcome in women less than 30 years of age with breast cancer.
  204. (2006). Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells.
  205. (2002). Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
  206. (2004). Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.
  207. (1994). Loss of heterozygosity and p53 gene mutations in breast cancer.
  208. (1995). Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
  209. (2002). Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
  210. (2004). Management of risk of breast carcinoma in postmenopausal women.
  211. (2004). Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.
  212. (2001). Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor).
  213. (1997). Methylation of the BRCA1 gene in sporadic breast cancer.
  214. (2002). Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer.
  215. (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors.
  216. (2003). MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.
  217. (2006). Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.
  218. (2001). Mistargeting of B-type lamins at the end of mitosis: implications on cell survival and regulation of lamins A/C expression.
  219. (2006). Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium.
  220. (2007). Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: agespecific prevalence and survival.
  221. (1996). Molecular characterization of AKAP149, a novel A kinase anchor protein with a KH domain.
  222. (2003). Molecular classification of familial non-BRCA1/BRCA2 breast cancer.
  223. (1998). Molecular cytogenetics of primary breast cancer by CGH.
  224. (2003). Molecular epidemiology of breast cancer: a review.
  225. (2005). Molecular evolution of breast cancer.
  226. (2000). Molecular portraits of human breast tumours.
  227. (1991). Mutations in the p53 gene in primary human breast cancers.
  228. (1989). Mutations in the p53 gene occur in diverse human tumour types.
  229. (2006). Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia.
  230. (2005). mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France.
  231. (1995). N-myc protein expression in human breast carcinoma: prognostic implications.
  232. (2005). Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.
  233. (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.
  234. (2004). Oncogenic pathways in hereditary and sporadic breast cancer.
  235. or = 35 years with primary breast carcinoma: disease features at presentation.
  236. (1997). Organelle-specific targeting of protein kinase AII (PKAII). Molecular and in situ characterization of murine A kinase anchor proteins that recruit regulatory subunits of PKAII to the cytoplasmic surface of mitochondria.
  237. (1995). Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.
  238. (2004). Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma.
  239. (2001). Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu.
  240. (2001). p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
  241. PAL31, a nuclear protein required for progression to the S phase.
  242. (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up.
  243. (2004). PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells.
  244. (2004). PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells.
  245. (2003). Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1.
  246. (2004). Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review.
  247. (2003). PKA-dependent binding of mRNA to the mitochondrial AKAP121 protein.
  248. (2003). Polymorphisms in the MTHFR gene are associated with breast cancer.
  249. (2007). Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
  250. (2001). Predicting the clinical status of human breast cancer by using gene expression profiles.
  251. (2007). Prediction of metastasis from low-malignant breast cancer by gene expression profiling.
  252. (2006). Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex.
  253. (2001). Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC.
  254. (2002). Prognosis of breast cancer and gene expression profiling using DNA arrays.
  255. (2006). Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
  256. (1988). Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis.
  257. (2003). Progranulin (acrogranin/PC cellderived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development.
  258. (2003). Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis.
  259. (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
  260. Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse.
  261. (1999). PTEN mutation spectrum and genotype-phenotype correlations in BannayanRiley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.
  262. (2004). Putative gene loci associated with carcinogenesis and metastasis of endocervical adenocarcinomas of uterus determined by conventional and array-based CGH.
  263. (2001). Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffinembedded tumor tissue.
  264. (2000). Quantitative mRNA expression analysis from formalin-fixed, paraffinembedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction.
  265. (2002). Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies.
  266. (2000). RAC-3 is a NF-kappa B coactivator.
  267. (1997). RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.
  268. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
  269. (2003). Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35.
  270. (2003). RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma.
  271. (2007). RbAp48 is a critical mediator controlling the transforming activity of human papillomavirus type 16 in cervical cancer.
  272. (2007). RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer.
  273. (2007). Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells.
  274. (2005). Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
  275. (2000). Recruitment of protein phosphatase 1 to the nuclear envelope by A-kinase anchoring protein AKAP149 is a prerequisite for nuclear lamina assembly.
  276. (1998). Reduced E-cadherin immunohistochemical expression in nodenegative breast carcinomas correlates with 10-year survival.
  277. (1999). Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
  278. (1991). Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
  279. (2004). Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators.
  280. (1999). Regulation of transcription by a protein methyltransferase.
  281. (1988). Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
  282. (2005). Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization.
  283. (2001). Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast.
  284. (1996). Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs.
  285. (2006). Reverse transcription using random pentadecamer primers increases yield and quality of resulting cDNA.
  286. (2001). Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a ratelimiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells.
  287. (2006). RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras.
  288. (1998). RNA from decades-old archival tissue blocks for retrospective studies.
  289. (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
  290. (2001). Secreted and cell surface genes expressed in benign and malignant colorectal tumors.
  291. (2002). Selection of an internal control gene for quantitation of mRNA in colonic tissues.
  292. (1997). Sex steroid hormones, bone mineral density, and risk of breast cancer.
  293. (2006). Short RNAs repress translation after initiation in mammalian cells.
  294. (2005). Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma.
  295. (1999). Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
  296. (2002). Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2.
  297. (1998). Steroid hormone receptors in breast cancer management.
  298. (1978). Steroid receptor analyses of nine human breast cancer cell lines.
  299. (2006). Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor.
  300. (1998). Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits.
  301. (2006). Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway.
  302. (1993). Striking differences in the epidemiological picture of breast cancer in urban and rural areas in Poland.
  303. (1990). Studies of the HER-2/neu proto-oncogene in human breast cancer.
  304. (2005). Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.
  305. (1998). Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.
  306. (2003). Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.
  307. (2005). The &quot;portrait&quot; of hereditary breast cancer.
  308. (2005). The Anp32 family of proteins containing leucine-rich repeats.
  309. (2001). The biological functions of Akinase anchor proteins.
  310. (1998). The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland.
  311. (2004). The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest.
  312. (2001). The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression.
  313. (2002). The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.
  314. (2000). The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients.
  315. (2003). The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.
  316. (2005). The distinctive nature of HER2-positive breast cancers.
  317. (2003). The granulin-epithelin precursor: a putative new growth factor for ovarian cancer.
  318. (2006). The granulinepithelin precursor is a steroid-regulated growth factor in endometrial cancer.
  319. (1994). The inherited component of cancer.
  320. (1999). The link between socioeconomic status and breast cancer--a possible explanation.
  321. (2001). The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
  322. (1996). The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age.
  323. (1992). The Nottingham Prognostic Index in primary breast cancer.
  324. (2004). The nuclear receptor coactivator AIB1 mediates insulin-like growth factor Iinduced phenotypic changes in human breast cancer cells.
  325. (1986). The relation between survival and age at diagnosis in breast cancer.
  326. (1976). The specificity of proteinase K against oxidized insulin B chain.
  327. (2004). The transcriptional coactivator p/CIP (NCoA-3) is up-regulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6.
  328. (1997). TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1.
  329. (2003). Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.
  330. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
  331. (1994). Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
  332. (2007). Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.
  333. (2005). Tumor-prone phenotype of the DDB2-deficient mice.
  334. (1997). Ultraviolet radiation sensitivity and reduction of telomeric silencing in Saccharomyces cerevisiae cells lacking chromatin assembly factor-I.
  335. (2002). under: prognosis and survival.
  336. (2001). Unlocking the archive--gene expression in paraffin-embedded tissue.
  337. (2002). Very young women (<35 years) with operable breast cancer: features of disease at presentation.
  338. (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
  339. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.